Courier Capital LLC Sells 57,138 Shares of Johnson & Johnson $JNJ

Courier Capital LLC cut its stake in Johnson & Johnson (NYSE:JNJ) by 88.6% in the third quarter, HoldingsChannel reports. The institutional investor owned 7,348 shares of the company’s stock after selling 57,138 shares during the quarter. Courier Capital LLC’s holdings in Johnson & Johnson were worth $1,945,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. Contravisory Investment Management Inc. boosted its stake in Johnson & Johnson by 54.2% in the 3rd quarter. Contravisory Investment Management Inc. now owns 6,692 shares of the company’s stock valued at $1,772,000 after buying an additional 2,351 shares in the last quarter. Catalyst Private Wealth LLC raised its stake in Johnson & Johnson by 3.6% during the third quarter. Catalyst Private Wealth LLC now owns 2,437 shares of the company’s stock worth $645,000 after acquiring an additional 84 shares in the last quarter. Salvus Wealth Management LLC raised its stake in Johnson & Johnson by 7.0% during the third quarter. Salvus Wealth Management LLC now owns 8,490 shares of the company’s stock worth $2,248,000 after acquiring an additional 553 shares in the last quarter. St. Clair Advisors LLC raised its stake in Johnson & Johnson by 1.5% during the third quarter. St. Clair Advisors LLC now owns 22,026 shares of the company’s stock worth $5,831,000 after acquiring an additional 327 shares in the last quarter. Finally, First County Bank CT lifted its holdings in shares of Johnson & Johnson by 2.9% during the third quarter. First County Bank CT now owns 6,582 shares of the company’s stock valued at $1,743,000 after acquiring an additional 184 shares during the period. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Price Performance

JNJ stock traded down $14.83 during midday trading on Tuesday, reaching $248.90. 16,613,205 shares of the company’s stock traded hands, compared to its average volume of 7,994,569. The company has a 50-day simple moving average of $266.01 and a two-hundred day simple moving average of $249.31. The company has a quick ratio of 0.81, a current ratio of 1.09 and a debt-to-equity ratio of 0.44. Johnson & Johnson has a 1-year low of $184.66 and a 1-year high of $281.07. The company has a market cap of $599.83 billion, a price-to-earnings ratio of 28.84, a PEG ratio of 2.65 and a beta of 0.21.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, October 13th. The company reported $2.59 EPS for the quarter, topping analysts’ consensus estimates of $2.53 by $0.06. The company had revenue of $25.40 billion for the quarter, compared to analyst estimates of $25.38 billion. Johnson & Johnson had a return on equity of 32.42% and a net margin of 21.48%. The business’s revenue was up 5.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.80 earnings per share. On average, analysts anticipate that Johnson & Johnson will post 11.18 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 8th. Investors of record on Tuesday, November 24th will be issued a $1.34 dividend. This represents a $5.36 dividend on an annualized basis and a dividend yield of 2.2%. The ex-dividend date of this dividend is Tuesday, November 24th. Johnson & Johnson’s payout ratio is currently 62.11%.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the stock. Morgan Stanley boosted their target price on shares of Johnson & Johnson from $284.00 to $294.00 and gave the company an “overweight” rating in a research note on Thursday, July 16th. Scotiabank reiterated an “outperform” rating and set a $305.00 target price on shares of Johnson & Johnson in a research report on Thursday, July 16th. HSBC increased their target price on shares of Johnson & Johnson from $290.00 to $320.00 and gave the stock a “buy” rating in a research report on Thursday, September 10th. Citigroup lifted their price target on shares of Johnson & Johnson from $298.00 to $303.00 and gave the company a “buy” rating in a report on Monday, October 5th. Finally, Wall Street Zen lowered shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a research report on Saturday, August 1st. One investment analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $276.22.

Johnson & Johnson News Summary

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: JNJ reported third-quarter adjusted EPS of $2.59, above the $2.53 analyst consensus, while revenue increased 5.9% year over year to approximately $25.4 billion. Johnson & Johnson Q3 earnings report
• Positive Sentiment: Management raised its 2026 outlook, lifting the reported sales midpoint to $101.2 billion and adjusted EPS midpoint to $11.10, supported by Innovative Medicine growth. Johnson & Johnson raises 2026 guidance
• Positive Sentiment: TREMFYA sales and encouraging long-term Crohn’s disease data provide support for JNJ’s pharmaceutical growth strategy, helping offset pressure from Stelara biosimilar competition. TREMFYA Crohn’s disease data
• Positive Sentiment: The company declared a quarterly dividend of $1.34 per share, reinforcing its appeal to income-focused investors. Johnson & Johnson dividend announcement
• Neutral Sentiment: JNJ said it is leaning toward spinning out its hips-and-knees business, a potential long-term restructuring catalyst but also an acknowledgment of challenges within MedTech. J&J hips-and-knees business spinoff
• Negative Sentiment: MedTech growth disappointed, particularly in cardiovascular and surgery markets outside the United States. Investors viewed the segment’s performance as evidence that the business may require further improvement. Investors focus on J&J MedTech
• Negative Sentiment: Reported net income fell sharply and GAAP EPS declined to $0.09 because of charges tied largely to the proposed talc litigation resolution, the Firefly Bio acquisition and the Sail Biomedicines collaboration. Johnson & Johnson quarterly report analysis
• Negative Sentiment: Investors appeared to treat the guidance increase as modest relative to elevated expectations, while new drug deals are expected to pressure 2027 earnings. Broader healthcare weakness and geopolitical disruption affecting device sales added to the selling pressure.

Insiders Place Their Bets

In related news, EVP Elizabeth Forminard sold 15,918 shares of the company’s stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $257.00, for a total transaction of $4,090,926.00. Following the transaction, the executive vice president owned 16,994 shares in the company, valued at $4,367,458. This represents a 48.37% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Jennifer Taubert sold 15,000 shares of the stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $263.36, for a total transaction of $3,950,400.00. Following the sale, the executive vice president directly owned 194,451 shares in the company, valued at approximately $51,210,615.36. This represents a 7.16% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 87,569 shares of company stock valued at $23,064,544. 0.16% of the stock is owned by corporate insiders.

Johnson & Johnson Company Profile

Johnson & Johnson (NYSE: JNJ) is a global healthcare company that develops, manufactures and markets products through two primary business segments: Innovative Medicine and MedTech. Its operations serve patients, healthcare professionals and consumers in markets around the world.

The Innovative Medicine segment focuses on prescription medicines in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.